[Skip to Navigation]
Sign In
Views 474
Citations 0
Comment & Response
June 10, 2021

Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker—Reply

Author Affiliations
  • 1Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio
  • 3Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
JAMA Oncol. 2021;7(8):1245-1246. doi:10.1001/jamaoncol.2021.1870

In Reply We thank Drs Cui and Zhang for their comments on our Brief Report.1 We share their interest in studying tumor mutation burden (TMB)—a predictive biomarker associated with the probability that tumors of many different cancer histologies will respond to checkpoint inhibitor immunotherapy. It would be wonderful if the specific numerical value of TMB (in mutations per megabase) that optimally predicted immunotherapy response was the exact same number for every type of cancer and if that numerical value were a convenient number, like 10. Alas, the universe is not so simple.

Add or change institution
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×